Co-Diagnostics (NASDAQ:CODX) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Co-Diagnostics (NASDAQ:CODX) issued its quarterly earnings data on Thursday. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02), Zacks reports. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%.

Co-Diagnostics Stock Performance

Shares of NASDAQ:CODX traded down $0.03 during trading on Thursday, hitting $0.39. The company’s stock had a trading volume of 705,748 shares, compared to its average volume of 181,234. The company has a market capitalization of $12.45 million, a PE ratio of -0.28 and a beta of 1.29. Co-Diagnostics has a fifty-two week low of $0.34 and a fifty-two week high of $2.23. The stock’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.90.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.